ads
Weather Icon

Sacramento

58°F, Overcast clouds

Top Categories

VIAJES

SALUD

REVISTA

POLÍTICA

Popular News

Spanish Magazines in Sacramento

Why Spanish Magazine in Sacramento Are Essential for...

Lay’s Potato Chips Recall

Lay’s Potato Chips Recall Could Pose a Deadly...

Premio Lo Nuestro 2025: Lista completa de artistas...

Karoline Leavitt

Karoline Leavitt Breaks the Barriers and Becomes the...

DJ Limbo Latino
ESPECTÁCULO

DJ Limbo Latino Presents New Bachata Version of “Hallelujah”

DJ Limbo Latino, renowned for blending diverse musical styles, releases a captivating bachata version of the timeless classic “Hallelujah.” This international collaboration features six talented Chilean artists—Dany Suavillo, Akai Rojas, Abisag, Diago, Eydan Valdes, and Rodriandre—creating a unique fusion of Latin rhythms and emotive vocals. Available on Spotify, Apple Music, and YouTube, this track promises to resonate with fans of bachata and timeless melodies alike.

Read More
bluebird bio Inc.
NOTICIAS

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio shared long-term data at the ASH Annual Meeting on ZYNTEGLO® (betibeglogene autotemcel), a one-time gene therapy for beta-thalassemia patients requiring regular transfusions. Results from up to 10 years of follow-up show durable transfusion independence, improved hemoglobin levels, reduced iron burden, and sustained safety outcomes. Most participants achieved long-term benefits, including discontinuation of iron chelation therapy and enhanced quality of life. The therapy continues to demonstrate its potential to transform the management of severe genetic diseases.

Read More
MiNA Therapeutics
NOTICIAS

MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting

MiNA Therapeutics presented promising preclinical data for its drug candidate, MTL-HBG , at the ASH Annual Meeting 2024. This treatment uses small activating RNA (aRNA) to increase fetal hemoglobin (HbF) production, protecting sickle cell patients from vaso-occlusive crises and organ damage. MTL-HBG showed levels greater than 20% of HbF, exceeding the recognized threshold for alleviating severe symptoms. Unlike gene therapies, MTL-HBG is delivered in vivo without preconditioning or complex cell engineering, and clinical studies are expected to begin in 2025.

Read More
Orca Bio
NOTICIAS

Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting

Orca Bio presentó datos prometedores sobre Orca-Q, su terapia inmunológica alogénica de células T de segunda generación, en la 66.ª Reunión Anual de ASH. Este enfoque no requiere profilaxis contra la enfermedad injerto contra huésped (GvHD) en pacientes con donantes completamente compatibles y mostró bajas tasas de GvHD, infecciones y mortalidad no relacionada con recaídas. En un ensayo de Fase 1, los pacientes tratados con Orca-Q tuvieron una supervivencia libre de recaídas del 85%, alcanzando el 90% en un subgrupo con condiciones específicas. Orca-Q busca redefinir la terapia celular alogénica al eliminar la necesidad de inmunosupresores, preservando la seguridad y eficacia.

Read More

SALES

miguel borges

miguel@dprimeramano.org

5385 Franklin Blvd g, Sacramento, CA 95820, United States

Play Store
Apple Store
Behance Rss Facebook Instagram Pinterest Twitter Youtube

Suscribirse al boletín informativo

Email Subscription Form

Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra  Política de Privacidad.